Andrew Spoljaric, MD
Neurology · Richmond, INNPI 1699773309
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $152,925 of the $163,341 with a category attached, or 93.6%. AbbVie accounts for 78.1% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $67,303 and has fallen 92.0% since, to $5,402 in 2025. Among neurology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $497.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$128K
- Biogen$15K
- Biohaven Pharmaceuticals, Inc.$13K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- Corium, LLC$780
- Vanda Pharmaceuticals Inc.$522
- plus $1K from 28 others
What the payments were for
- Consulting fees$7800%
- Speaking & faculty fees$152,92594%
- Travel & lodging$4,3143%
- Food & beverage$5,3013%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 189 | $127,531 |
| Biogen | 19 | $15,372 |
| Biohaven Pharmaceuticals, Inc. | 13 | $13,188 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $4,552 |
| Corium, LLC | 1 | $780 |
| Vanda Pharmaceuticals Inc. | 18 | $522 |
| Eisai Inc. | 5 | $177 |
| Novartis | 10 | $173 |
| Sanofi | 5 | $115 |
| TG Therapeutics, Inc. | 3 | $103 |
| Sunovion Pharmaceuticals Inc. | 8 | $80 |
| MDD US Operations, LLC | 5 | $74 |
| Avanir Pharmaceuticals, Inc. | 3 | $68 |
| EMD Serono, Inc. | 4 | $65 |
| Lundbeck LLC | 4 | $63 |
| UCB, Inc. | 3 | $59 |
| Amgen | 3 | $47 |
| Promius Pharma LLC | 3 | $45 |
| Scilex Pharmaceuticals Inc. | 2 | $34 |
| Adamas Pharmaceuticals, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Octapharma USA, Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Merz North America, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Aucta Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Strongbridge US Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| CSL Behring | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$69,489
- UBRELVY$54,124
- NURTEC ODT$17,604
- QULIPTA$10,025
- ADLARITY$780
How this compares
$163,341 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $138,255 |
| NuplazidPimavanserin Tartrate | 15 | $129,175 |
| NuedextaDextromethorphan Hbr/Quinidine | 53 | $94,658 |
| FycompaPerampanel | 54 | $85,877 |
| AptiomEslicarbazepine Acetate | 20 | $78,672 |
| GocovriAmantadine Hcl | 21 | $56,974 |
| UbrelvyUbrogepant | 35 | $48,050 |
| QuliptaAtogepant | 29 | $47,133 |
| NeurontinGabapentin | 12 | $33,854 |
| Nurtec OdtRimegepant Sulfate | 19 | $22,758 |
| Emgality PenGalcanezumab-Gnlm | 26 | $17,578 |
| Topiramate ErTopiramate | 16 | $17,271 |
| VraylarCariprazine Hcl | 12 | $17,014 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 136 | $16,738 |
| Lacosamide | 80 | $15,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $29 | $138,25511 claims |
| Acadia Pharmaceuticals IncNuplazid | $16 | $129,17515 claims |
| AbbVieUbrelvy, Qulipta, Vraylar | $127,531 | $112,19776 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $68 | $94,65853 claims |
| Eisai Inc.Fycompa | $177 | $85,87754 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $80 | $78,67220 claims |
| MDD US Operations, LLCGocovri | $74 | $56,97421 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $17 | $45,00655 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.
Other neurology in Richmond
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
- Andrea HallerFort Wayne$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.